Joint bleeds in Von Willebrand disease: Impact on joint integrity, -function and daily life.
Completed
- Conditions
- patients with moderate or severe Von Willebrand disease
- Registration Number
- NL-OMON24768
- Lead Sponsor
- niversity Medical Center Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Patients with moderate or severe VWD treated with coagulation factor or desmopressin for 1 or more joint bleeds as documented in their MF.
Exclusion Criteria
Inability of the patient or the patients parents to give informed consent
A recent joint bleed without complete recovery
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Existence of arthropathy: the number and percentage of patients with arthropathy among the different patient groups.<br>Severity of arthropathy: separate and cumulative scores of HJHS and Pettersson. <br>Impact of arthropathy on physical functioning and participation: time to complete the figure 8 walking test, separate and cumulative scores of (Ped)HAL and IPA questionnaires. <br>Impact on quality of life: separate and cumulative scores of D-AIMS2-affect and MPQ-DLV questionnaires.<br>
- Secondary Outcome Measures
Name Time Method Influence of the severity of the coagulation defect on the existence, severity and impact of arthropathy<br>Number and sites of affected joints<br>Quantitative use of desmopressin and coagulation factors in relation to the existence of arthropathy <br>Prophylactic use of coagulation factors in relation to the existence of arthropathy<br>